Gilead Sciences (GILD) blows away estimates (Max Headroom Style)

Gilead Sciences, Inc. (NASDAQ:GILD) shares are up 6% in after hours trading on Tuesday, as the company reported huge revenue growth last quarter.

To give you an idea of just how far they blew out estimates, Total revenues for the quarter were $2.03 billion, up 42% from $1.43 billion in the comparable quarter last year. Analysts projected that the company would report revenue of $1.92 billion.

After their last earnings call, back in October, I wrote an article titled "Why are Gilead Sciences (NASDAQ:GILD) shares falling?"

I love it when a plan comes together. Here is an excerpt from the article:

REALLY? Revenue increases 31 pct, but investors are bailing because the AIDS drug Truvada grossed $620.6M instead of $626M, falling short by just $6M?

Fellow Stockmasters, this is a special situation and a great opportunity to get in on shares of GILD for value. Tamiflu is just gravy, and you need to get on the gravy train.

Again, fellow Masters of Stock Mastery, get in on Gilead before it's too late. Shares should be trading in the $60 range in short order.

I'll leave you with this quote from Max Headroom:

Max Headroom: Now, I'm no librarian, in fact, I don't know what star sign I am. But, as a famous person once said, "You can fool some of the people some of the time, but you can't fool all of the people all of the time." And as I - another more famous person - once said, "If you don't teach them to read, you can fool them whenever you like."